RU2018139999A3 - - Google Patents

Info

Publication number: RU2018139999A3
Authority: RU; Russia

Application number

RU2018139999A

Other versions

RU2018139999A (ru

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2016-05-16

Filing date

2017-05-11

Publication date

2020-11-26

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=58765966&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2018139999(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2017-05-11 Application filed filed Critical

2020-06-17 Publication of RU2018139999A publication Critical patent/RU2018139999A/ru

2020-11-26 Publication of RU2018139999A3 publication Critical patent/RU2018139999A3/ru

2021-12-13 Application granted granted Critical

2021-12-13 Publication of RU2761870C2 publication Critical patent/RU2761870C2/ru

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/04—Amoebicides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Organic Chemistry (AREA)
Epidemiology (AREA)
Immunology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Microbiology (AREA)
Mycology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Communicable Diseases (AREA)
Virology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Cell Biology (AREA)
Zoology (AREA)
Toxicology (AREA)
Biochemistry (AREA)
Genetics & Genomics (AREA)
Gastroenterology & Hepatology (AREA)
Pulmonology (AREA)
Oncology (AREA)
Tropical Medicine & Parasitology (AREA)
Engineering & Computer Science (AREA)
Oil, Petroleum & Natural Gas (AREA)
Dispersion Chemistry (AREA)
Inorganic Chemistry (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

RU2018139999A 2016-05-16 2017-05-11 Состав, содержащий агонист tlr, и способы применения RU2761870C2 (ru)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201662337322P	2016-05-16	2016-05-16
US62/337,322		2016-05-16
PCT/US2017/032287 WO2017200852A1 (en)	2016-05-16	2017-05-11	Formulation containing tlr agonist and methods of use

Publications (3)

Publication Number	Publication Date
RU2018139999A RU2018139999A (ru)	2020-06-17
RU2018139999A3 true RU2018139999A3 (ru)	2020-11-26
RU2761870C2 RU2761870C2 (ru)	2021-12-13

Family

ID=58765966

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
RU2018139999A RU2761870C2 (ru)	2016-05-16	2017-05-11	Состав, содержащий агонист tlr, и способы применения

Country Status (16)

Country	Link
US (4)	US11344619B2 (ru)
EP (2)	EP4112638A1 (ru)
JP (1)	JP7195148B2 (ru)
KR (1)	KR102392974B1 (ru)
CN (1)	CN109310773B (ru)
AU (1)	AU2017268144B2 (ru)
BR (1)	BR112018073690B1 (ru)
CA (1)	CA3023968A1 (ru)
DK (1)	DK3458475T3 (ru)
ES (1)	ES2929054T3 (ru)
HU (1)	HUE059605T2 (ru)
IL (3)	IL314130A (ru)
MX (1)	MX2018014086A (ru)
RU (1)	RU2761870C2 (ru)
WO (1)	WO2017200852A1 (ru)
ZA (1)	ZA201807497B (ru)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2017200852A1 (en)	2016-05-16	2017-11-23	Infectious Disease Research Institute	Formulation containing tlr agonist and methods of use
CN108096576B (zh) *	2017-12-28	2021-09-03	中国医学科学院医学实验动物研究所	Tlr8激活剂在制备结核疫苗佐剂中的用途及其制备的结核疫苗
SG11202112870WA (en) *	2019-05-23	2021-12-30	The Univ Of Montana	Vaccine adjuvants based on tlr receptor ligands
CA3142935A1 (en) *	2019-06-10	2020-12-17	Infectious Disease Research Institute	Methods and compositions of astrovirus replicons
US11679163B2 (en)	2019-09-20	2023-06-20	Hdt Bio Corp.	Compositions and methods for delivery of RNA
GB2605312B (en)	2020-03-23	2024-06-26	Hdt Bio Corp	Compositions and methods for delivery of RNA
CA3173408A1 (en)	2020-12-23	2022-06-30	Access To Advanced Health Institute	Solanesol vaccine adjuvants and methods of preparing same
CA3232719A1 (en)	2021-09-22	2023-03-30	Steven Gregory REED	Sars-cov-2 rna vaccine compositions and methods of use
CA3232566A1 (en)	2021-09-22	2023-03-30	Hdt Bio Corp.	Dried nanoparticle compositions
AU2022351009A1 (en)	2021-09-22	2024-04-11	Hdt Bio Corp.	Rna vaccines against infectious diseases
WO2025043016A2 (en) *	2023-08-21	2025-02-27	The Board Of Trustees Of The Leland Stanford Junior University	A universal vaccine strategy for conferring protection against diverse pathogens

Family Cites Families (133)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US669275A (en)	1897-08-06	1901-03-05	John H Watts	Means for transmitting power.
US3598122A (en)	1969-04-01	1971-08-10	Alza Corp	Bandage for administering drugs
US3598123A (en)	1969-04-01	1971-08-10	Alza Corp	Bandage for administering drugs
US4286592A (en)	1980-02-04	1981-09-01	Alza Corporation	Therapeutic system for administering drugs to the skin
US4314557A (en)	1980-05-19	1982-02-09	Alza Corporation	Dissolution controlled active agent dispenser
US4379454A (en)	1981-02-17	1983-04-12	Alza Corporation	Dosage for coadministering drug and percutaneous absorption enhancer
US4769330A (en)	1981-12-24	1988-09-06	Health Research, Incorporated	Modified vaccinia virus and methods for making and using the same
US4436727A (en)	1982-05-26	1984-03-13	Ribi Immunochem Research, Inc.	Refined detoxified endotoxin product
IL73534A (en)	1983-11-18	1990-12-23	Riker Laboratories Inc	1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
US4855238A (en)	1983-12-16	1989-08-08	Genentech, Inc.	Recombinant gamma interferons having enhanced stability and methods therefor
US4568343A (en)	1984-10-09	1986-02-04	Alza Corporation	Skin permeation enhancer compositions
GB8508845D0 (en)	1985-04-04	1985-05-09	Hoffmann La Roche	Vaccinia dna
FI861417A0 (fi)	1985-04-15	1986-04-01	Endotronics Inc	Hepatitis b ytantigen framstaelld med rekombinant-dna-teknik, vaccin, diagnostiskt medel och cellinjer samt foerfaranden foer framstaellning daerav.
US5169763A (en)	1986-04-08	1992-12-08	Transgene S.A., Institut Pasteur	Viral vector coding glycoprotein of HIV-1
US4948587A (en)	1986-07-08	1990-08-14	Massachusetts Institute Of Technology	Ultrasound enhancement of transbuccal drug delivery
US4767402A (en)	1986-07-08	1988-08-30	Massachusetts Institute Of Technology	Ultrasound enhancement of transdermal drug delivery
US5075109A (en)	1986-10-24	1991-12-24	Southern Research Institute	Method of potentiating an immune response
EP1088830A3 (en)	1987-06-22	2004-04-07	Medeva Holdings B.V.	Hepatitis b surface antigen particles
US4780212A (en)	1987-07-31	1988-10-25	Massachusetts Institute Of Technology	Ultrasound enchancement of membrane permeability
US4897268A (en)	1987-08-03	1990-01-30	Southern Research Institute	Drug delivery system and method of making the same
WO1989001973A2 (en)	1987-09-02	1989-03-09	Applied Biotechnology, Inc.	Recombinant pox virus for immunization against tumor-associated antigens
GB2232892B (en)	1988-02-23	1991-07-24	John Mark Tucker	Occlusive body for administering a physiologically active substance
US4912094B1 (en)	1988-06-29	1994-02-15	Ribi Immunochem Research Inc.	Modified lipopolysaccharides and process of preparation
GB8819209D0 (en)	1988-08-12	1988-09-14	Research Corp Ltd	Polypeptide & dna encoding same
US4999403A (en)	1988-10-28	1991-03-12	Exxon Chemical Patents Inc.	Graft polymers of functionalized ethylene-alpha-olefin copolymer with polypropylene, methods of preparation, and use in polypropylene compositions
AU626961B2 (en)	1988-12-16	1992-08-13	De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezonheid En Cultuur	Pneumolysin mutants and pneumococcal vaccines made therefrom
EP0454781B1 (en)	1989-01-23	1998-12-16	Chiron Corporation	Recombinant cells for therapies of infection and hyperproliferative disorders and preparation thereof
ATE159031T1 (de)	1989-07-25	1997-10-15	Smithkline Biolog	Antigene sowie verfahren zu deren herstellung
EP0845537A1 (en)	1989-08-18	1998-06-03	Chiron Corporation	Recombinant retroviruses delivering vector constructs to target cells
US6120769A (en)	1989-11-03	2000-09-19	Immulogic Pharmaceutical Corporation	Human T cell reactive feline protein (TRFP) isolated from house dust and uses therefor
US5256643A (en)	1990-05-29	1993-10-26	The Government Of The United States	Human cripto protein
GB9106048D0 (en)	1991-03-21	1991-05-08	Smithkline Beecham Biolog	Vaccines
US6277969B1 (en)	1991-03-18	2001-08-21	New York University	Anti-TNF antibodies and peptides of human tumor necrosis factor
DE122007000023I1 (de)	1991-07-19	2007-08-09	Univ Queensland St Lucia	Impfsstoff gegen Humanes Papillomavirus (typ 18)
US5464387A (en)	1991-07-24	1995-11-07	Alza Corporation	Transdermal delivery device
US6197311B1 (en)	1991-07-25	2001-03-06	Idec Pharmaceuticals Corporation	Induction of cytotoxic T-lymphocyte responses
CA2115364A1 (en)	1991-08-16	1993-03-04	Philip L. Felgner	Composition and method for treating cystic fibrosis
ATE177755T1 (de)	1991-11-16	1999-04-15	Smithkline Beecham Biolog	Hybrides protein zwischen cs aus plasmodium und hbsag
US6057427A (en)	1991-11-20	2000-05-02	Trustees Of Dartmouth College	Antibody to cytokine response gene 2(CR2) polypeptide
EP0650370A4 (en)	1992-06-08	1995-11-22	Univ California	METHODS AND COMPOSITIONS TARGETED ON SPECIFIC TISSUES.
CA2137361A1 (en)	1992-06-10	1993-12-23	W. French Anderson	Vector particles resistant to inactivation by human serum
DE122007000097I1 (de)	1992-06-25	2008-03-27		Papillomavirus vakzine
ATE188613T1 (de)	1992-06-25	2000-01-15	Smithkline Beecham Biolog	Adjuvantien enthaltende impfstoffzusammensetzung
US5786148A (en)	1996-11-05	1998-07-28	Incyte Pharmaceuticals, Inc.	Polynucleotides encoding a novel prostate-specific kallikrein
GB2269175A (en)	1992-07-31	1994-02-02	Imperial College	Retroviral vectors
US5437951A (en)	1992-09-03	1995-08-01	The United States Of America As Represented By The Department Of Health And Human Services	Self-assembling recombinant papillomavirus capsid proteins
DE05075889T1 (de)	1993-03-09	2006-10-05	The University Of Rochester	Herstellung von menschlichem Papilloma-Virus HBV-11-Capsid-Protein L1 und virusähnlichen Teilchen
AU681687B2 (en)	1993-07-15	1997-09-04	Minnesota Mining And Manufacturing Company	Imidazo(4,5-c)pyridin-4-amines
US6106824A (en)	1993-08-13	2000-08-22	The Rockefeller University	Expression of growth associated protein B-50/GAP-43 in vitro and in vivo
DE69433695T2 (de)	1993-11-02	2004-08-12	Matsushita Electric Industrial Co., Ltd., Kadoma	Halbleiterbauelement mit Aggregat von Mikro-Nadeln aus Halbleitermaterial
US5885211A (en)	1993-11-15	1999-03-23	Spectrix, Inc.	Microporation of human skin for monitoring the concentration of an analyte
US5814599A (en)	1995-08-04	1998-09-29	Massachusetts Insitiute Of Technology	Transdermal delivery of encapsulated drugs
US5458140A (en)	1993-11-15	1995-10-17	Non-Invasive Monitoring Company (Nimco)	Enhancement of transdermal monitoring applications with ultrasound and chemical enhancers
US5693531A (en)	1993-11-24	1997-12-02	The United States Of America As Represented By The Department Of Health And Human Services	Vector systems for the generation of adeno-associated virus particles
GB9326253D0 (en)	1993-12-23	1994-02-23	Smithkline Beecham Biolog	Vaccines
US5688506A (en)	1994-01-27	1997-11-18	Aphton Corp.	Immunogens against gonadotropin releasing hormone
US5457041A (en)	1994-03-25	1995-10-10	Science Applications International Corporation	Needle array and method of introducing biological substances into living cells using the needle array
US5591139A (en)	1994-06-06	1997-01-07	The Regents Of The University Of California	IC-processed microneedles
DK0772619T4 (da)	1994-07-15	2011-02-21	Univ Iowa Res Found	Immunmodulatoriske oligonukleotider
US7037712B2 (en)	1994-07-26	2006-05-02	Commonwealth Scientific And Industrial Research Organisation	DNA encoding ovine adenovirus (OAV287) and its use as a viral vector
GB9415319D0 (en)	1994-07-29	1994-09-21	Medical Res Council	HSV viral vector
ES2264563T3 (es)	1994-10-07	2007-01-01	Loyola University Of Chicago	Particulas semejantes al virus del papiloma, proteinas de fusion y procedimiento para su preparacion.
FR2727689A1 (fr)	1994-12-01	1996-06-07	Transgene Sa	Nouveau procede de preparation d'un vecteur viral
AU4727296A (en)	1995-02-24	1996-09-11	Cantab Pharmaceuticals Research Limited	Polypeptides useful as immunotherapeutic agents and methods of polypeptide preparation
US5843464A (en)	1995-06-02	1998-12-01	The Ohio State University	Synthetic chimeric fimbrin peptides
US5993800A (en)	1995-06-05	1999-11-30	Bristol-Myers Squibb Company	Methods for prolonging the expression of a heterologous gene of interest using soluble CTLA4 molecules and an antiCD40 ligand
US5981215A (en)	1995-06-06	1999-11-09	Human Genome Sciences, Inc.	Human criptin growth factor
US6309847B1 (en)	1995-07-05	2001-10-30	Yeda Research And Development Co. Ltd.	Method for detecting or monitoring the effectiveness of treatment of T cell mediated diseases
US5618275A (en)	1995-10-27	1997-04-08	Sonex International Corporation	Ultrasonic method and apparatus for cosmetic and dermatological applications
US5656016A (en)	1996-03-18	1997-08-12	Abbott Laboratories	Sonophoretic drug delivery system
US5955306A (en)	1996-09-17	1999-09-21	Millenium Pharmaceuticals, Inc.	Genes encoding proteins that interact with the tub protein
US6797276B1 (en)	1996-11-14	2004-09-28	The United States Of America As Represented By The Secretary Of The Army	Use of penetration enhancers and barrier disruption agents to enhance the transcutaneous immune response
US7033598B2 (en)	1996-11-19	2006-04-25	Intrabrain International N.V.	Methods and apparatus for enhanced and controlled delivery of a biologically active agent into the central nervous system of a mammal
DE19654221B4 (de)	1996-12-23	2005-11-24	Telefonaktiebolaget Lm Ericsson (Publ)	Leitungsanschlußschaltkreis
US5840871A (en)	1997-01-29	1998-11-24	Incyte Pharmaceuticals, Inc.	Prostate-associated kallikrein
US6977073B1 (en)	1997-02-07	2005-12-20	Cem Cezayirli	Method for stimulating an immune response
AR012035A1 (es)	1997-02-25	2000-09-27	Corixa Corp	Metodo para detectar el cancer de prostata, metodo para monitorear el desarrollo del cancer de prostata, anticuerpo monoclonal que se une a un polipeptido, una cantidad terapeutica eficaz de anticuerpos monoclonales para preparar medicamentos y equipo para diagnostico
WO1999003884A2 (en)	1997-07-21	1999-01-28	North American Vaccine, Inc.	Modified immunogenic pneumolysin, compositions and their use as vaccines
US6749856B1 (en)	1997-09-11	2004-06-15	The United States Of America, As Represented By The Department Of Health And Human Services	Mucosal cytotoxic T lymphocyte responses
US7459524B1 (en)	1997-10-02	2008-12-02	Emergent Product Development Gaithersburg Inc.	Chlamydia protein, sequence and uses thereof
EP2228384A1 (en)	1997-11-28	2010-09-15	Merck Serono Biodevelopment	Chlamydia trachomatis genomic sequence and polypeptides, fragments thereof and uses thereof, in particular for the diagnosis, prevention and treatment of infection
UA67760C2 (ru)	1997-12-11	2004-07-15	Міннесота Майнінг Енд Мануфакчурінг Компані	Имидазонафтиридины и их применение для индуцирования биосинтеза цитокинов
KR100824105B1 (ko)	1998-02-05	2008-04-21	글락소스미스클라인 바이오로지칼즈 에스.에이.	백신접종을 위한 융합 단백질 및 조성물의 제조를 위해사용되는 ｍａｇｅ 군으로부터의 종양 관련 항원 유도체 및이들을 암호화하고 있는 핵산 서열
FR2775601B1 (fr)	1998-03-03	2001-09-21	Merial Sas	Vaccins vivants recombines et adjuves
CZ302870B6 (cs)	1998-04-07	2011-12-28	Corixa Corporation	Polynukleotid, polypeptid, farmaceutický prostredek, vakcínový prostredek a jejich použití k lécbe a prevenci infekce tuberkulózou
GB2336310B (en)	1998-04-14	2003-09-10	Stowic Resources Ltd	Method of manufacturing transdermal patches
JP2002511266A (ja)	1998-04-15	2002-04-16	ルードヴィッヒインスティテュートフォーキャンサーリサーチ	腫瘍関連核酸及びその使用
US6322532B1 (en)	1998-06-24	2001-11-27	3M Innovative Properties Company	Sonophoresis method and apparatus
AU762812B2 (en)	1998-07-14	2003-07-03	Corixa Corporation	Compositions and methods for therapy and diagnosis of prostate cancer
US6110929A (en)	1998-07-28	2000-08-29	3M Innovative Properties Company	Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof
US6692752B1 (en)	1999-09-08	2004-02-17	Smithkline Beecham Biologicals S.A.	Methods of treating human females susceptible to HSV infection
US6375944B1 (en)	1998-09-25	2002-04-23	The Wistar Institute Of Anatomy And Biology	Methods and compositions for enhancing the immunostimulatory effect of interleukin-12
US7001770B1 (en)	1998-10-15	2006-02-21	Canji, Inc.	Calpain inhibitors and their applications
US6734172B2 (en)	1998-11-18	2004-05-11	Pacific Northwest Research Institute	Surface receptor antigen vaccines
US6770445B1 (en)	1999-02-26	2004-08-03	Pacific Northwest Research Institute	Methods and compositions for diagnosing carcinomas
GB9906177D0 (en)	1999-03-17	1999-05-12	Oxford Biomedica Ltd	Anti-viral vectors
IL145982A0 (en)	1999-04-19	2002-07-25	Smithkline Beecham Biolog	Vaccines
US6685699B1 (en)	1999-06-09	2004-02-03	Spectrx, Inc.	Self-removing energy absorbing structure for thermal tissue ablation
AU6884200A (en)	1999-08-26	2001-03-19	Biovitrum Ab	Novel response element
US7084256B2 (en)	1999-09-24	2006-08-01	Large Scale Biology Corporation	Self antigen vaccines for treating B cell lymphomas and other cancers
JP4162813B2 (ja)	1999-10-28	2008-10-08	久光製薬株式会社	イオントフォレーシス装置
US6218186B1 (en)	1999-11-12	2001-04-17	Trustees Of The University Of Pennsylvania	HIV-MSCV hybrid viral vector for gene transfer
US6974588B1 (en)	1999-12-07	2005-12-13	Elan Pharma International Limited	Transdermal patch for delivering volatile liquid drugs
AU2001233132A1 (en)	2000-01-31	2001-08-07	The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, The National Institutes Of Health	Hybrid adeno-retroviral vector for the transfection of cells
ATE444372T1 (de)	2000-05-31	2009-10-15	Human Gene Therapy Res Inst	Methode und zusammensetzungen für effizienten gentransfer durch transcomplementierende vektoren
US6969704B1 (en)	2000-08-25	2005-11-29	The Trustees Of Columbia University In The City Of New York	Methods for suppressing early growth response—1protein (Egr-1) to reduce vascular injury in a subject
US6844192B2 (en)	2001-06-29	2005-01-18	Wake Forest University	Adenovirus E4 protein variants for virus production
US6752995B2 (en)	2002-04-15	2004-06-22	Board Of Regents, The University Of Texas System	Nucleic acid and polypeptide sequences useful as adjuvants
US6908453B2 (en)	2002-01-15	2005-06-21	3M Innovative Properties Company	Microneedle devices and methods of manufacture
US6676961B1 (en)	2002-03-06	2004-01-13	Automated Carrier Technologies, Inc.	Transdermal patch assembly
US7018345B2 (en)	2002-12-06	2006-03-28	Hisamitsu Pharmaceutical Co., Inc.	Iontophoresis system
KR101494056B1 (ko)	2003-10-03	2015-02-16	쓰리엠 이노베이티브 프로퍼티즈 컴파니	피라졸로피리딘 및 그의 유사체
CA2597170A1 (en)	2005-02-08	2006-08-17	Id Biomedical Corporation Of Quebec C.O.B. As Glaxosmithkline Biological S North America	Pharmaceutical compositions
DE102005032175A1 (de)	2005-07-09	2007-01-18	Krones Ag	Behälter-Behandlungsmaschine und Verfahren zum Laden und Entladen einer Behälter-Behandlungsmaschine
ATE383895T1 (de)	2005-07-19	2008-02-15	Holzapfel Gmbh & Co Kg Geb	Auftriebshilfe
US20090181078A1 (en) *	2006-09-26	2009-07-16	Infectious Disease Research Institute	Vaccine composition containing synthetic adjuvant
WO2008057696A2 (en) *	2006-10-10	2008-05-15	Juvaris Biotherapeutics, Inc.	Compositions of pattern recognition receptor-ligand: lipid complexes and methods of use thereof
EP2136836B8 (en)	2007-04-04	2017-04-12	Infectious Disease Research Institute	Immunogenic compositions comprising mycobacterium tuberculosis polypeptides and fusions thereof
US8709445B2 (en) *	2007-07-31	2014-04-29	Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center	Vaccination with killed but metabolically active (KBMA) protozoans with toll-like receptor agonists
US8793881B2 (en)	2008-08-15	2014-08-05	Stanley Black & Decker, Inc.	Utility knife with blade lock
TWI549688B (zh)	2009-06-05	2016-09-21	美國疾病傳染研究機構	合成的葡萄吡喃糖基脂質佐劑
CN102844047B (zh) *	2009-09-02	2017-04-05	诺华股份有限公司	含tlr活性调节剂的免疫原性组合物
PT2606047T (pt)	2010-08-17	2017-04-07	3M Innovative Properties Co	Composições, formulações e métodos de um composto lipidado modificador da resposta imunitária
KR20140026392A (ko) *	2011-03-02	2014-03-05	노파르티스 아게	저용량의 항원 및/또는 보조제를 갖는 조합 백신
BR112013032675A2 (pt) *	2011-06-19	2017-08-08	Vaxine Pty Ltd	composição adjuvante de vacina compreendendo partículas de inulina
US9375471B2 (en)	2012-03-08	2016-06-28	Glaxosmithkline Biologicals Sa	Adjuvanted formulations of booster vaccines
JP2015514696A (ja) *	2012-03-18	2015-05-21	グラクソスミスクラインバイオロジカルズソシエテアノニム	ヒト・パピローマウイルスに対するワクチン接種方法
EP3065829B1 (en)	2013-11-08	2021-05-19	University of Virginia Patent Foundation	Compositions and methods for treating melanoma
CN112521464A (zh)	2014-03-26	2021-03-19	葛兰素史密丝克莱恩生物有限公司	突变型葡萄球菌抗原
US10881729B2 (en)	2014-04-18	2021-01-05	Children's Medical Center Corporation	Vaccine adjuvant compositions
WO2016010788A1 (en)	2014-07-15	2016-01-21	The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services	Polyketal particles including a cpg oligodeoxynucleotide for the treatment of lung cancer
CN104800843B (zh) *	2015-04-02	2017-07-04	中国农业科学院兰州兽医研究所	一种用于弓形虫感染预防的药剂及应用
WO2017200852A1 (en)	2016-05-16	2017-11-23	Infectious Disease Research Institute	Formulation containing tlr agonist and methods of use

2017
- 2017-05-11 WO PCT/US2017/032287 patent/WO2017200852A1/en not_active Ceased
- 2017-05-11 AU AU2017268144A patent/AU2017268144B2/en active Active
- 2017-05-11 JP JP2018560185A patent/JP7195148B2/ja active Active
- 2017-05-11 DK DK17725451.3T patent/DK3458475T3/da active
- 2017-05-11 EP EP22170931.4A patent/EP4112638A1/en active Pending
- 2017-05-11 US US16/098,615 patent/US11344619B2/en active Active
- 2017-05-11 EP EP17725451.3A patent/EP3458475B1/en active Active
- 2017-05-11 MX MX2018014086A patent/MX2018014086A/es unknown
- 2017-05-11 HU HUE17725451A patent/HUE059605T2/hu unknown
- 2017-05-11 ES ES17725451T patent/ES2929054T3/es active Active
- 2017-05-11 IL IL314130A patent/IL314130A/en unknown
- 2017-05-11 KR KR1020187035495A patent/KR102392974B1/ko active Active
- 2017-05-11 BR BR112018073690-2A patent/BR112018073690B1/pt active IP Right Grant
- 2017-05-11 IL IL299285A patent/IL299285B2/en unknown
- 2017-05-11 CA CA3023968A patent/CA3023968A1/en active Pending
- 2017-05-11 RU RU2018139999A patent/RU2761870C2/ru active
- 2017-05-11 CN CN201780035091.4A patent/CN109310773B/zh active Active
2018
- 2018-11-08 ZA ZA2018/07497A patent/ZA201807497B/en unknown
- 2018-11-15 IL IL263028A patent/IL263028B2/en unknown
2022
- 2022-04-28 US US17/731,718 patent/US20220257754A1/en active Pending
- 2022-04-28 US US17/731,671 patent/US12440559B2/en active Active
2025
- 2025-01-17 US US19/030,990 patent/US20250242016A1/en active Pending

Also Published As

Publication number	Publication date
IL299285B2 (en)	2024-12-01
US20250242016A1 (en)	2025-07-31
JP7195148B2 (ja)	2022-12-23
CA3023968A1 (en)	2017-11-23
IL263028B1 (en)	2023-03-01
US12440559B2 (en)	2025-10-14
AU2017268144A1 (en)	2018-11-29
CN109310773A (zh)	2019-02-05
IL299285A (en)	2023-02-01
JP2019519504A (ja)	2019-07-11
ZA201807497B (en)	2019-06-26
MX2018014086A (es)	2019-09-18
KR20190008545A (ko)	2019-01-24
EP3458475A1 (en)	2019-03-27
RU2018139999A (ru)	2020-06-17
ES2929054T3 (es)	2022-11-24
CN109310773B (zh)	2022-04-26
WO2017200852A1 (en)	2017-11-23
EP3458475B1 (en)	2022-07-27
IL263028A (en)	2018-12-31
US20220257754A1 (en)	2022-08-18
AU2017268144B2 (en)	2021-07-22
US20220280640A1 (en)	2022-09-08
US20190142935A1 (en)	2019-05-16
HUE059605T2 (hu)	2022-11-28
IL299285B1 (en)	2024-08-01
KR102392974B1 (ko)	2022-05-02
DK3458475T3 (da)	2022-09-12
IL263028B2 (en)	2023-07-01
IL314130A (en)	2024-09-01
RU2761870C2 (ru)	2021-12-13
BR112018073690A2 (pt)	2019-02-26
EP4112638A1 (en)	2023-01-04
US11344619B2 (en)	2022-05-31
BR112018073690B1 (pt)	2022-05-24

Publication	Publication Date	Title
BR122021017409A2 (ru)	2019-03-12
BR112018003417A2 (ru)	2018-10-02
BR112019002665A2 (ru)	2019-07-23
BR112019009366A2 (ru)	2019-07-23
BR112019009203A2 (ru)	2019-07-23
BR202016030146U2 (ru)	2018-07-17
CN303537604S (ru)	2016-01-06
CN303537760S (ru)	2016-01-06
CN303535548S (ru)	2016-01-06
CN303535879S (ru)	2016-01-06
CN303535882S (ru)	2016-01-06
CN303536131S (ru)	2016-01-06
CN303536207S (ru)	2016-01-06
CN303536214S (ru)	2016-01-06
CN303536235S (ru)	2016-01-06
CN303536441S (ru)	2016-01-06
CN303536492S (ru)	2016-01-06
CN303536497S (ru)	2016-01-06
CN303536515S (ru)	2016-01-06
CN303536550S (ru)	2016-01-06
CN303536594S (ru)	2016-01-06
CN303536629S (ru)	2016-01-06
CN303536867S (ru)	2016-01-06
CN303537445S (ru)	2016-01-06
CN303570516S (ru)	2016-01-27